Inovio Pharma (INO) Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Inovio Pharma (INO) Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients

Inovio Pharmaceuticals (INO) PT Lowered to $6 at RBC Capital

November 15, 2024 6:33 AM EST

RBC Capital analyst Gregory Renza lowered the price target on Inovio Pharmaceuticals (NASDAQ: INO) to $6.00 (from $7.00) while maintaining a Sector Perform rating.

The analyst comments "INOs 3Q print affirms INO-3107 in RRP as the companys primary focus during a time... More